Table 2. Univariate and multivariate analysis of OS rate (log-rank test).
| Univariate analysis |
|
|
|
|---|---|---|---|
| Clinical parameter | n | Median OS (months) | p value |
|
Age |
|
|
|
| < 75 y |
231 |
58.9 |
0.0472 |
| ≥ 75 y |
38 |
36.7 |
|
|
Gender |
|
|
|
| Male |
92 |
42.6 |
0.0328 |
| Female |
181 |
62.7 |
|
|
Primary tumor localization |
|
|
|
| Sigmoid colon |
100 |
68 |
0.0039 |
| Colon/Rectum |
173 |
43.5 |
|
|
WHO performance status |
|
|
|
| 0–1 |
258 |
58.4 |
0.0027 |
| 2–3 |
15 |
19 |
|
|
Karnofsky performance status | |||
| ≤ 80 |
16 |
19.4 |
0.0036 |
| > 80 |
257 |
58.1 |
|
|
Lymph node involvement grade |
|
|
|
| Involved lymph nodes |
60 |
65.3 |
0.0031 |
| Uninvolved lymph nodes |
231 |
46.3 |
|
|
Pretreatment CEA level (ng/ml) |
|
|
|
| ≤ 5 |
170 |
25.6 |
< 0.0001 |
| > 5 | 89 | 76.3 | |
| Multivariate analysis |
|
|
|
|---|---|---|---|
| Clinical parameter | HR (95% CI) | p value | |
| Primary tumor localization |
|
|
|
| Sigmoid colon vs. Rectum/Colon |
0.53 (0.35–0.81) |
0.0032 |
|
|
Lymph node involvement grade |
|
|
|
| Involved vs. Uninvolved |
1.94 (1.17–3.24) |
0.0107 |
|
|
WHO performance status |
|
|
|
| 0–1 vs. 2 |
0.34 (0.18–0.64) |
0.0008 |
|
|
Karnofsky performance status |
|
|
|
| ≤ 80 vs. > 80 |
NS |
> 0.05 |
|
|
Pretreatment CEA level (ng/ml) |
|
|
|
| ≤ 5 vs. > 5 |
2.68 (2.09–3.44) |
< 0.0001 |
|
|
Age |
|
|
|
| ≤ 75 vs. > 75 y |
NS |
> 0.05 |
|
|
Gender |
|
|
|
| Male vs. female | NS | > 0.05 |
NS, not significant.